SPPI Key Stats
- Biotech Stock Mailbag: Amarin, MannKind, Palatin May 24
- Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th A... May 23
- SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure May 20
- Spectrum Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May... May 20
- Spectrum Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Tran... May 20
- Outlook for the Most Shorted Stocks May 17
- SPECTRUM PHARMACEUTICALS INC Financials May 17
- The 5 Dumbest Things on Wall Street This Week: May 17 May 17
- [video] 5 Dumbest Things on Wall Street May 17
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma May 17
SPPI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Spectrum Pharmaceuticals is down 25.15% over the last year vs S&P 500 Total Return up 27.77%, Elan down 3.44%, and Agenus down 20.82%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for SPPI
Pro Report PDF for SPPI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SPPI Pro Report PDF
Pro Strategies Featuring SPPI
Did Spectrum Pharmaceuticals make it into our Pro Portfolio Strategies?